Nucor Upgraded by UBS to Buy with $190 Target
UBS raises Nucor to Buy with a $190 target after a pullback, highlighting stronger than expected Q1 guidance and impr...
A high index level often signals stronger market momentum or potential overbought conditions. Grasp its implications to adjust exposure and risk.
25,713 articlesUBS raises Nucor to Buy with a $190 target after a pullback, highlighting stronger than expected Q1 guidance and impr...
As confirmation hearings approach, kevin warsh’s undisclosed wealth becomes a flashpoint, with a 69-page filing leavi...
Axsome Therapeutics rode a powerful April rally driven by Auvelity performance and pipeline momentum. This article br...
Amentum faces a pivotal Q2 2026 earnings season. This deep dive breaks down backlog, margins, and guidance, with prac...
Legislation known as the Clarity Act moves through Congress, aiming to legalize real estate tokenization. If enacted,...
Investors are weighing Alibaba's AI and cloud ambitions against profits and regulatory headwinds. This guide breaks d...
Quantum computing is edging toward mainstream impact, with a $72 billion forecast by 2035. This article uncovers thre...
Ford is mounting a renewed effort in a longtime European battleground. This article breaks down the plan, the pitfall...
Over the last year, ISCV outpaced IJJ, but market cycles can change on a dime. This guide explains why that edge may ...
A bold investment thesis hinges on the AI inference niche. After June 3, the market could reward execution as much as...
CytomX sits at a crossroads as 2025 earnings unfold, with pipeline updates, collaboration deals, and cost discipline ...
As markets shift in 2026, Netflix and Disney face different risk-reward profiles. This analysis weighs dividends, val...